Aperture Venture Partners is a healthcare-focused venture capital firm committed to working with exceptional entrepreneurs to build innovative companies in the medical device, biopharmaceutical, diagnostic and healthcare IT sectors. Select portfolio companies include Cameron Health, CardioMEMS, Conor Medsystems, Inspire Medical, Mako Surgical, Axonics and Interlace Medical.
Arboretum Ventures is a venture capital firm specializing in the healthcare sector. Founded in 2002, the firm manages $235 million in capital and has invested in more than 30 companies, five of which have exited with an aggregate valuation of approximately $1 billion. These successes have positioned Arboretum Ventures’ first two funds as top-quartile performers according to recognized industry benchmarks.
Headquartered in Ann Arbor, Arboretum invests throughout the United States, but with a preference for Midwest opportunities. The team targets capital efficient companies that can meaningfully reduce healthcare costs in our areas of expertise: devices, diagnostics, services, and IT.
LSP is one of Europe’s largest and most experienced healthcare investment firms. With a track record going back more than 25 years, it has built up an investment house that is dedicated to only one task: seeking, nurturing and growing healthcare investment opportunities with the potential to have a positive impact on society. LSP believes such opportunities create the most value for all parties.
From its offices in Amsterdam, Munich and Boston, its team aims to back the smartest inventors with the best ideas. While their goal is to develop products and technologies that have a positive impact on society, their objective is to help inventors achieve their goals. By definition, success is often accompanied by financial returns. The combination of contributing to society and the prospect of associated financial returns is why investors entrust LSP to invest their capital.
Hostplus is a national superannuation fund for those that live and love Australian hospitality, tourism, recreation and sport. The Australian Hotels Association and United Voice jointly established the fund in 1987. Hostplus is one of the largest in the country with over one million members, 170,000 employers and $30 billion in funds under management.
H. Carnegie & Co. is one of Australia’s premier alternative asset managers based in Sydney, Australia. The fund was launched in 2011 by Mark Carnegie who has a long and successful track record in principal investing in the Australian, Asian and North American markets.
Carnegie, with over $320mn of funds under management, targets investments across venture and expansion capital, stressed/complex transactions, operating real estate and shareholder activism. The fund includes two innovation investment fund (“IIF”) allocations from the Australian Government totaling $60mn for venture related investments. In March 2013, Carnegie was awarded an IIF allocation of $40mn, the biggest ever made under this program.
Mark Carnegie, his team and the Carnegie investment committees have a significant and extensive profile and network within the Australian private investment markets resulting in an unparalleled flow of proprietary Australian-based investment opportunities and the support of a strong network of co-investors.
Built on a foundation that leverages 30 years of North American venture capital experience, the Lumira Ventures team has substantial experience helping to build transformational health and life science companies.
Their goal is to make investments in market leading companies and work in partnership with those companies to develop and implement strategies to build significant businesses that in turn allow us to generate profitable exits that maximize returns within a reasonable time frame.
As partners in our businesses they are committed to the success of our portfolio companies. We roll up our sleeves and work side by side with our entrepreneurs, their management teams and our syndication partners – leveraging our internal resources, knowledge networks, deep industry expertise and relationships, as well as our operational and leadership experience to help the businesses achieve their full potential.
Join our mailing list for invitations to studies along with company announcements.
NOTE: The Carillon Mitral Contour System has received CE Mark (0344) and is available for sale in Europe and other countries that recognize CE Mark.
CAUTION: Investigational Device. Limited by United States law to investigational use.